Pfenex Inc
Change company Symbol lookup
Select an option...
PFNX Pfenex Inc
BAC Bank of America Corp
DLTR Dollar Tree Inc
SOLCF SOL Global Investments Corp
MLTI Credit Suisse X-Links Multi-Asset High Income ETN
JPM-E JPMorgan Chase & Co
BSET Bassett Furniture Industries Inc
INDB Independent Bank Corp
CPHI China Pharma Holdings Inc
DRWB Laurel Road Bank
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Closing Price
$3.93
Day's Change
-0.07 (-1.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.23
Day's Low
3.92
Volume
(Below Average)
Volume:
53,537

10-day average volume:
61,420
53,537

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.